RNAZ (TransCode Therapeutics) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNAZ TransCode Therapeutics Inc RNAZ
32 GF Score
Price $4.96
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Short-term investments?

Short-term investments only applies to insurance companies.

RNAZ
32GF Score
TransCode Therapeutics Inc RNAZ
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
32GF Score

Get the complete analysis for RNAZ

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.96
Price